Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...

Elevra’s Chief Executive Officer and Managing Director, Mr Lucas Dow, said: “The NAL Expansion PFS confirms a compelling value proposition for Elevra, with a high-return brownfield expansion that ...

Dakota Gold Corp. (NYSE American: DC) ("Dakota Gold" or the "Company") is pleased to provide results from the Pre-Feasibility Study ("PFS") metallurgical test program for its Richmond Hill Oxide Heap ...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They ...

A chemotherapy-free regimen offered durable disease control for certain patients with advanced breast cancer, according to results of the phase 1/phase 2 ASPIRE trial.The regimen — which consists of ...

Researchers pooled data from phase 3 BRUIN CLL-313 and BRUIN CLL-314 clinical trials to assess efficacy and safety of pirtobrutinib in treatment-naive patients with chronic lymphocytic leukemia /small ...

Summit Therapeutics is positioned as a high-conviction buy into the November 2026 FDA PDUFA decision for ivonescimab in NSCLC ...

Guardian Metal Resources is transitioning from explorer to U.S. tungsten developer, anchored by the Pilot Mountain project.

The phase 1b/2 ELEVATE study evaluated everolimus, an mTORC1 inhibitor, plus elacestrant, a next-generation, oral selective ER degrader, in adult patients with ER+/HER2- breast cancer.

Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where ...

Analysts propose that this positive readout in ES-SCLC could see Imdelltra move into the frontline setting within this indication.